Immunoproteasome overexpression underlies the pathogenesis of thyroid oncocytes and primary hypothyroidism: Studies in humans and mice

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Kimura, Hiroaki J ^a   Chen, Cindy Y ^a   Tzou, Shey Cherng ^a   Rocchi, Roberto ^a   Landek Salgado, Melissa A ^a   Suzuki, Koichi ^b   Kimura, Miho ^a   Rose, Noel R ^a,c   Caturegli, Patrizio ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN; PROTEASOME; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR LMP2; TRANSCRIPTION FACTOR LMP7; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CONTROLLED STUDY; GENE DELETION; GENE OVEREXPRESSION; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; ONCOCYTOMA; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CANCER; ANIMAL; C57BL MOUSE; CELL NUCLEUS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNE SYSTEM; METABOLISM; PATHOLOGY; PHYSIOLOGY; THYROID GLAND; THYROID PARAFOLLICULAR CELL; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ADENOMA, OXYPHILIC; ANIMALS; CELL NUCLEUS; FEMALE; GENE EXPRESSION REGULATION; HASHIMOTO DISEASE; HUMANS; HYPOTHYROIDISM; IMMUNE SYSTEM; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OXYPHIL CELLS; PHENOTYPE; PROTEASOME ENDOPEPTIDASE COMPLEX; THYROID GLAND;

EID: 70849127013     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007857     Document Type: Article

References (39)

1. Cooper GS, Stroehla BC (2003) The epidemiology of autoimmune diseases. Autoimmun Rev 2: 119-125.
2. Caturegli P, Ruggere C (2005) Karl Hurthle! Now, who was he? Thyroid 15: 121-123.
3. Tallini G, Carcangiu ML, Rosai J (1992) Oncocytic neoplasms of the thyroid gland. Acta Pathol Jpn 42: 305-315.
4. Montone KT, Baloch ZW, LiVolsi VA (2008) The thyroid Hurthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med 132: 1241-1250.
5. Caturegli P, Hejazi M, Suzuki K, Dohan O, Carrasco N, et al. (2000) Hypothyroidism in transgenic mice expressing IFN-gamma in the thyroid. Proc Natl Acad Sci U S A 97: 1719-1724.
6. Kimura H, Kimura M, Westra WH, Rose NR, Caturegli P (2005) Increased thyroidal fat and goitrous hypothyroidism induced by interferon-gamma. Int J Exp Pathol 86: 97-106.
7. Tanaka K (2009) The proteasome: overview of structure and functions. Proc Jpn Acad Ser B Phys Biol Sci 85: 12-36.
8. Kloetzel PM (2004) Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat Immunol 5: 661-669.
9. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, et al. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622.
10. Maksymowych WP, Tao S, Vaile J, Suarez-Almazor M, Ramos-Remus C, et al. (2000) LMP2 polymorphism is associated with extraspinal disease in HLA-B27 negative Caucasian and Mexican Mestizo patients with ankylosing spondylitis. J Rheumatol 27: 183-189.
11. Casp CB, She JX, McCormack WT (2003) Genes of the LMP/TAP cluster are associated with the human autoimmune disease vitiligo. Genes Immun 4: 492-499.
12. Kramer U, Illig T, Grune T, Krutmann J, Esser C (2007) Strong associations of psoriasis with antigen processing LMP and transport genes TAP differ by gender and phenotype. Genes Immun 8: 513-517.
13. Egerer K, Kuckelkorn U, Rudolph PE, Ruckert JC, Dorner T, et al. (2002) Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol 29: 2045-2052.
14. Scheffler S, Kuckelkorn U, Egerer K, Dorner T, Reiter K, et al. (2008) Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (beta1i), MECL1 (beta2i) and LMP7 (beta5i). Rheumatology (Oxford) 47: 622-626.
15. Egerer T, Martinez-Gamboa L, Dankof A, Stuhlmuller B, Dorner T, et al. (2006) Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjogren's syndrome. Arthritis Rheum 54: 1501-1508.
16. Krause S, Kuckelkorn U, Dorner T, Burmester GR, Feist E, et al. (2006) Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders. Ann Rheum Dis 65: 1021-1027.
17. Hayashi T, Faustman D (1999) NOD mice are defective in proteasome production and activation of NF-kappaB. Mol Cell Biol 19: 8646-8659.
18. Hayashi T, Kodama S, Faustman DL (2000) Reply to 'LMP2 expression and proteasome activity in NOD mice'. Nat Med 6: 1065-1066.
19. Kessler BM, Lennon-Dumenil AM, Shinohara ML, Lipes MA, Ploegh HL (2000) LMP2 expression and proteasome activity in NOD mice. Nat Med 6: 1064; author reply 1065-1066.
20. Runnels HA, Watkins WA, Monaco JJ (2000) LMP2 expression and proteasome activity in NOD mice. Nat Med 6: 1064-1065; author reply 1065-1066.
21. Vives-Pi M, Vargas F, James RF, Trowsdale J, Costa M, et al. (1997) Proteasome subunits, low-molecular-mass polypeptides 2 and 7 are hyperexpressed by target cells in autoimmune thyroid disease but not in insulin-dependent diabetes mellitus: implications for autoimmunity. Tissue Antigens 50: 153-163.
22. Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, et al. (1998) Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med 187: 97-104.
23. Groettrup M, Standera S, Stohwasser R, Kloetzel PM (1997) The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc Natl Acad Sci U S A 94: 8970-8975.
24. Adams J (2002) Development of the proteasome inhibitor PS-341. Oncologist 7: 9-16.
25. Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2006) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57: 33-47.
26. Fissolo N, Kraus M, Reich M, Ayturan M, Overkleeft H, et al. (2008) Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol 38: 2401-2411.
27. Neubert K, Meister S, Moser K, Weisel F, Maseda D, et al. (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14: 748-755.
28. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, et al. (2009) Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113: 4667-4676.
29. Lindenthal C, Weich N, Chia YS, Heussler V, Klinkert MQ (2005) The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites. Parasitology 131: 37-44.
30. Hu G, Lin G, Wang M, Dick L, Xu RM, et al. (2006) Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. Mol Microbiol 59: 1417-1428.
31. Bonuccelli G, Sotgia F, Capozza F, Gazzerro E, Minetti C, et al. (2007) Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. Cell Cycle 6: 1242-1248.
32. Chade AR, Herrmann J, Zhu X, Krier JD, Lerman A, et al. (2005) Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. J Am Soc Nephrol 16: 1005-1012.
33. Fukai T (2007) Targeting proteasome worsens atherosclerosis. Circ Res 101: 859-861.
34. Herrmann J, Saguner AM, Versari D, Peterson TE, Chade A, et al. (2007) Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res 101: 865-874.
35. Ludwig A, Meiners S (2008) Targeting of the proteasome worsens atherosclerosis? Circ Res 102: e37.
36. Benvenga S (2008) Update on thyroid cancer. Horm Metab Res 40: 323-328.
37. Nussbaum AK, Rodriguez-Carreno MP, Benning N, Botten J, Whitton JL (2005) Immunoproteasome-deficient mice mount largely normal CD8+ T cell responses to lymphocytic choriomeningitis virus infection and DNA vaccination. J Immunol 175: 1153-1160.
38. Durbin JE, Hackenmiller R, Simon MC, Levy DE (1996) Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443-450.
39. Saha S, Sparks AB, Rago C, Akmaev V, Wang CJ, et al. (2002) Using the transcriptome to annotate the genome. Nat Biotechnol 20: 508-512.